EMS-CHEMIE HOLDING Balance Sheet Health
Financial Health criteria checks 5/6
EMS-CHEMIE HOLDING has a total shareholder equity of CHF2.0B and total debt of CHF22.8M, which brings its debt-to-equity ratio to 1.1%. Its total assets and total liabilities are CHF2.4B and CHF388.0M respectively. EMS-CHEMIE HOLDING's EBIT is CHF504.8M making its interest coverage ratio -79.4. It has cash and short-term investments of CHF357.1M.
Key information
1.1%
Debt to equity ratio
CHF 22.85m
Debt
| Interest coverage ratio | -79.4x |
| Cash | CHF 357.10m |
| Equity | CHF 2.03b |
| Total liabilities | CHF 388.01m |
| Total assets | CHF 2.42b |
Recent financial health updates
Is EMS-CHEMIE HOLDING (VTX:EMSN) A Risky Investment?
Sep 20
We Think EMS-CHEMIE HOLDING (VTX:EMSN) Can Stay On Top Of Its Debt
Apr 07Recent updates
EMS-CHEMIE HOLDING (VTX:EMSN) May Have Issues Allocating Its Capital
Dec 19Pinning Down EMS-CHEMIE HOLDING AG's (VTX:EMSN) P/E Is Difficult Right Now
Dec 01Estimating The Intrinsic Value Of EMS-CHEMIE HOLDING AG (VTX:EMSN)
Nov 13Is EMS-CHEMIE HOLDING (VTX:EMSN) A Risky Investment?
Sep 20Investors Could Be Concerned With EMS-CHEMIE HOLDING's (VTX:EMSN) Returns On Capital
Aug 29Estimating The Fair Value Of EMS-CHEMIE HOLDING AG (VTX:EMSN)
Aug 04EMS-CHEMIE HOLDING AG's (VTX:EMSN) Shareholders Might Be Looking For Exit
Jun 13Returns On Capital Signal Difficult Times Ahead For EMS-CHEMIE HOLDING (VTX:EMSN)
May 22We Think EMS-CHEMIE HOLDING (VTX:EMSN) Can Stay On Top Of Its Debt
Apr 07Estimating The Intrinsic Value Of EMS-CHEMIE HOLDING AG (VTX:EMSN)
Mar 20The Returns At EMS-CHEMIE HOLDING (VTX:EMSN) Aren't Growing
Feb 06Financial Position Analysis
Short Term Liabilities: EMSN's short term assets (CHF1.6B) exceed its short term liabilities (CHF294.7M).
Long Term Liabilities: EMSN's short term assets (CHF1.6B) exceed its long term liabilities (CHF93.3M).
Debt to Equity History and Analysis
Debt Level: EMSN has more cash than its total debt.
Reducing Debt: EMSN's debt to equity ratio has increased from 0.6% to 1.1% over the past 5 years.
Debt Coverage: EMSN's debt is well covered by operating cash flow (2314.2%).
Interest Coverage: EMSN earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:53 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EMS-CHEMIE HOLDING AG is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantin Wiechert | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Aron Ceccarelli | Berenberg |